Search results for "bevacizumab"

showing 10 items of 162 documents

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

2013

Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional d…

GynecologyOncologymedicine.medical_specialtyendocrine system diseasesBevacizumabtarget therapybusiness.industrymedicine.medical_treatmentGold standardbevacizumabmedicine.diseaseMalignancyCarboplatinchemistry.chemical_compoundovarian cancerPaclitaxelchemistryInternal medicinemedicineplatinumbusinessOvarian cancerPathologicalAdjuvantmedicine.drugJournal of Cancer Therapy
researchProduct

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of …

2018

PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corr…

Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Intravitreal injection of bevacizumab induces inflammatory alterations in a uveitis experimental model.

2010

PurposeBevacizumab is currently used as an intravitreal agent in the treatment of inflammatory-associated eye diseases. The aim of the current study is to explore the effects of the intravitreal injection of bevacizumab on aqueous humour cytokines and chemokines in an experimental uveitis model.MethodsEndotoxin-induced uveitis was induced in rats by footpad injections. Bevacizumab was administered by intravitreal injection (75 μg in 3–μL samples) and different chemokine and cytokine proteins were quantified in aqueous humor.ResultsIntravitreal administration of bevacizumab led to a several-fold increase of RANTES, MCP-1, and IFN-γ concentrations in aqueous humor of endotoxin-treated rats.Co…

LipopolysaccharidesMaleVascular Endothelial Growth Factor AChemokinegenetic structuresBevacizumabmedicine.medical_treatmentInflammationAngiogenesis InhibitorsEnzyme-Linked Immunosorbent AssayPharmacologyAntibodies Monoclonal HumanizedAqueous HumorUveitisInterferon-gammaMedicineAnimalsChemokine CCL5Chemokine CCL2biologybusiness.industryAqueous humourGeneral MedicineIntravitreal administrationmedicine.diseaseeye diseasesRatsBevacizumabOphthalmologyDisease Models AnimalCytokineRats Inbred LewMonoclonalIntravitreal Injectionsbiology.proteinCytokinessense organsmedicine.symptombusinessUveitismedicine.drugEuropean journal of ophthalmology
researchProduct

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled ana…

2021

Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC).Individual patient data of 2190 patients enrolled in 10 prospective FFCD (Fédération Francophone de Cancérologie Digestive) trials were analysed. Severe early toxicity was defined as the occurrence of grade ≥III toxicity within 3 months after initiation of chemotherapy (ET3).Patients received monotherapy based on 5-FU (n = 1068), a cytotoxic doublet (n = 395) or tritherapy with a cytotoxic doublet plus anti-VEGF agent or a cytotoxic triplet (n = 727). The patients received 5-FU (100%), Irino…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudiesNeoplasm MetastasisAgedAfliberceptChemotherapyPerformance statusbusiness.industryMiddle AgedPrognosismedicine.diseaseOxaliplatinIrinotecanTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityFemaleColorectal Neoplasmsbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

2018

Background: Scant real-world data exist on the clinical outcomes associated with the use of bevacizumab-containing chemotherapy (B+CT) in patients with metastatic colorectal cancer (mCRC). The primary objective of the GRETA cohort study was to compare the overall survival (OS) of patients with mCRC treated with first-line B+CT versus chemotherapy (CT) alone, in an Italian clinical practice setting. Materials and Methods: Incident patients with mCRC were identified during the period 2010–2012 from five population-based cancer registries in Italy. Cases were linked to regional health care utilization databases to obtain the entire spectrum of health services provided to each patient. Patients…

Male0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabPropensity scoreColorectal cancerHealth Outcomes and Economics of Cancer CarePopulationSettore MED/42 - Igiene Generale E ApplicataCohort StudiesColorectal neoplasm03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSurvival analysiInternal medicineObservational studymedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studybusiness.industryHazard ratioCancerMiddle Agedmedicine.diseaseBevacizumab030104 developmental biologyOncology030220 oncology & carcinogenesisPropensity score matchingCohortFemaleColorectal Neoplasmsbusinessmedicine.drugCohort study
researchProduct

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR…

2017

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. METHODS: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRY…

Male0301 basic medicineOncologyColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeEGFR Antibody0302 clinical medicineAntineoplastic Agents ImmunologicalNeoplasias ColorrectaisMedicineNeoplasm MetastasisRandomized Controlled Trials as Topicpredictive valuePanitumumabHazard ratiotumour sideAntibodies MonoclonalHematologyPrognosisChemotherapy regimenErbB ReceptorsBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyBevacizumabcolorectal cancerGenes ras03 medical and health sciencesAnticorpos MonoclonaisInternal medicineHumansChemotherapybusiness.industryAntineoplásicos ImunológicosOdds ratiomedicine.diseaserandomised trial030104 developmental biologyGenes rasHuman medicinebusinessprognosticanti-EGFR treatment
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

2014

Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15%) discontinued the diet for poor tolerability. No serious adverse events attri…

MaleCancer ResearchStatement (logic)medicine.medical_treatmentSalvage treatmentPilot ProjectsBioinformaticsGastroenterologyMicegliomaClinical endpoint1306 Cancer ResearchglucoseArticlesMiddle AgedCombined Modality TherapyBevacizumabTreatment OutcomeTolerabilityOncologyketogenic dietFemale2730 OncologyDiet Ketogenicmedicine.drugAdultmedicine.medical_specialtyBevacizumabMice NudeAntineoplastic Agents610 Medicine & healthMistakeRecurrent GliomaBiologyAntibodies Monoclonal HumanizedInternal medicineGliomamedicineAnimalsHumansddc:610Adverse effectAgedbusiness.industryRecurrent glioblastomaGeneral surgeryKetosisNeoplasms Experimentalmedicine.diseaseSurvival Analysis10040 Clinic for NeurologySurgeryQuality of LifeNeoplasm Recurrence LocalKetosisGlioblastomabusinessmetabolismfeasibilityKetogenic dietInternational Journal of Oncology
researchProduct

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid

2017

OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed …

MaleDegeneracion macular asociada a la edad no neovascularVisual acuityTriamcinolone acetonidegenetic structuresFluido subretinianoAngiogenesis InhibitorsFundus (eye)Triamcinolone0302 clinical medicineDegeneración macular asociada a la edad no neovascular Fluido intrarretiniano Fluido subretiniano Intraretinal fluid Intravitreal therapies Non-neovascular age related macular degeneration Spectral domain optical coherence tomography Subretinal fluid Terapias intravítreas Tomografía de coherencia óptica de dominio espectralFluorescein AngiographyTomografia de coherencia optica de dominio espectralAged 80 and overmedicine.diagnostic_testSubretinal FluidExudates and TransudatesGeneral MedicineFluorescein angiographyFluido intrarretinianoBevacizumabTreatment Outcomemedicine.anatomical_structureIntravitreal InjectionsFemalemedicine.symptomIntravitreal therapiesTomography Optical Coherencemedicine.drugSubretinal fluidmedicine.medical_specialtyBevacizumabRetinal DrusenRetinaSpectral domain optical coherence tomography03 medical and health sciencesNon-neovascular age related macular degenerationRanibizumabOphthalmologymedicineHumansAgedRetinabusiness.industryMacular degenerationmedicine.diseaseTerapias intravitreaseye diseasesSurgeryWet Macular Degeneration030221 ophthalmology & optometryIntraretinal fluidsense organsRanibizumabbusiness030217 neurology & neurosurgeryArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

2013

Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical beneit in advanced non-squamous non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or biological markers have been identiied and validated for baseline patient selection. preclinical indings suggest an important role for myeloid-derived inlammatory cells, such as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inlammatory index, the neutrophil-toly…

MaleOncologyCancer ResearchLung NeoplasmsNeutrophilsmedicine.medical_treatmentPlatinum CompoundsMonocyteCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsNeutrophil-to-lymphocyte ratioUnivariate analysisadvanced non-small cell lung cancerMiddle AgedBevacizumabAngiogenesiTreatment OutcomeOncologyMolecular MedicineFemalemedicine.symptomLung cancermedicine.drugmedicine.medical_specialtyBevacizumabInflammationAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicinemedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioLung cancerAdverse effectAgedNeoplasm StagingRetrospective StudiesPharmacologyInflammationChemotherapyBedside to Bench ReportPlatelet Countbusiness.industryRetrospective cohort studymedicine.diseaseMultivariate AnalysisImmunologybusinessSystemic inflammatory status
researchProduct